Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > An example of deceptive headlines for Adstiladrin

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Dec 09, 2023 1:40pm

275 Views

Post# 35776337

RE:An example of deceptive headlines for Adstiladrin

Yes - very deceptive. And this kind of thing is done a lot. If Theralase were to play that game and we end up with a 35% CRR at 3 years, our headline might read:

More than one half of Theralase patients with high-risk BCG-unresponsive disease were recurrence free at 3 years

DJDawg wrote:
https://www.medpagetoday.com/meetingcoverage/suo/107650

The headline is

First Gene Therapy for Non-Muscle-Invasive Bladder Cancer Offers Durable Response

— A quarter patients with high-risk, BCG-unresponsive disease were recurrence free at 3 years

Whereas what it should read is a quarter of those who responded AT ALL were recurrence free at 3 years.

Or it could read

12% of those initialy treated were recurrence free at 3 years.